Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin [clinicaltrials:NCT00516750]
Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin [clinicaltrials:NCT00516750]
Bio2RDF identifier
NCT00516750
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00516750
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... , doxorubicin, and cisplatin.
brief title [clinicaltrials_vocabulary:brief-title]
Gene Expression Profiling in P ...... ne, Doxorubicin, and Cisplatin
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
completion date [clinicaltrials_vocabulary:completion-date]
2009-02-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
Prim ...... nts are followed for 3 years.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2007-08-14T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
recurrent bladder cancer
stage II bladder cancer
stage III bladder cancer
stage IV bladder cancer
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-07-09T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00516750
official title [clinicaltrials_vocabulary:official-title]
Phase II Clinical Trial Concer ...... ity of Invasive Bladder Cancer
org study id [clinicaltrials_vocabulary:org-study-id]
TRIC-UHA-GU-03-01
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2009-02-01T00:00:00Z
secondary id [clinicaltrials_vocabulary:secondary-id]
CDR0000561303
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2007-07-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2008-03-01T00:00:00Z
why stopped [clinicaltrials_vocabulary:why-stopped]
Withdrawn due to lack of enrollment.
identifier
clinicaltrials:NCT00516750
title
Gene Expression Profiling in P ...... ne, Doxorubicin, and Cisplatin
@en
type
label
Gene Expression Profiling in P ...... n [clinicaltrials:NCT00516750]
@en